Ocuphire Pharma Stock Analysis
OCUP Stock | USD 1.53 0.01 0.65% |
Ocuphire Pharma is undervalued with Real Value of 6.18 and Target Price of 20.2. The main objective of Ocuphire Pharma stock analysis is to determine its intrinsic value, which is an estimate of what Ocuphire Pharma is worth, separate from its market price. There are two main types of Ocuphire Pharma's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Ocuphire Pharma's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Ocuphire Pharma's stock to identify patterns and trends that may indicate its future price movements.
The Ocuphire Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Ocuphire Pharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Ocuphire Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Ocuphire Pharma's ongoing operational relationships across important fundamental and technical indicators.
Ocuphire |
Ocuphire Stock Analysis Notes
About 14.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.91. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Ocuphire Pharma recorded a loss per share of 0.46. The entity last dividend was issued on the 6th of November 2020. The firm had 1:4 split on the 6th of November 2020. Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan. Ocuphire Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Ocuphire Pharma contact MBA MD at (248) 957-9024 or learn more at https://www.ocuphire.com.Ocuphire Pharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Ocuphire Pharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Ocuphire Pharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Ocuphire Pharma generated a negative expected return over the last 90 days | |
Ocuphire Pharma may become a speculative penny stock | |
Ocuphire Pharma has high historical volatility and very poor performance | |
Ocuphire Pharma has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 19.05 M. Net Loss for the year was (9.99 M) with loss before overhead, payroll, taxes, and interest of (14.58 M). | |
Ocuphire Pharma currently holds about 17.15 M in cash with (1.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
Ocuphire Pharma has a frail financial position based on the latest SEC disclosures | |
Latest headline from finance.yahoo.com: Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting |
Ocuphire Pharma Upcoming and Recent Events
Earnings reports are used by Ocuphire Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ocuphire Pharma previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024 Upcoming Quarterly Report | View | |
20th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
4th of April 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Ocuphire Largest EPS Surprises
Earnings surprises can significantly impact Ocuphire Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-03-24 | 2021-12-31 | -0.29 | -0.35 | -0.06 | 20 | ||
2022-11-04 | 2022-09-30 | -0.29 | -0.22 | 0.07 | 24 | ||
2022-08-12 | 2022-06-30 | -0.33 | -0.25 | 0.08 | 24 |
Ocuphire Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ocuphire Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ocuphire Pharma backward and forwards among themselves. Ocuphire Pharma's institutional investor refers to the entity that pools money to purchase Ocuphire Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Squarepoint Ops Llc | 2023-12-31 | 61.2 K | American Century Companies Inc | 2023-12-31 | 60.3 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 56.1 K | Northern Trust Corp | 2023-12-31 | 51.9 K | Anson Funds Management Lp | 2023-12-31 | 49.3 K | Victory Capital Management Inc. | 2023-12-31 | 46.9 K | Kestra Private Wealth Services, Llc | 2023-12-31 | 42.3 K | Jane Street Group, Llc | 2023-12-31 | 34.7 K | Blair William & Co | 2023-12-31 | 33.3 K | Vanguard Group Inc | 2023-12-31 | 927.8 K | Rice Hall James & Associates, Llc | 2023-12-31 | 571.8 K |
Ocuphire Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 38.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ocuphire Pharma's market, we take the total number of its shares issued and multiply it by Ocuphire Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Ocuphire Profitablity
Ocuphire Pharma's profitability indicators refer to fundamental financial ratios that showcase Ocuphire Pharma's ability to generate income relative to its revenue or operating costs. If, let's say, Ocuphire Pharma is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Ocuphire Pharma's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Ocuphire Pharma's profitability requires more research than a typical breakdown of Ocuphire Pharma's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.21) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.21. Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.19) | (0.19) | |
Return On Capital Employed | (0.21) | (0.22) | |
Return On Assets | (0.19) | (0.19) | |
Return On Equity | (0.20) | (0.21) |
Management Efficiency
Ocuphire Pharma has return on total asset (ROA) of (0.1283) % which means that it has lost $0.1283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2077) %, meaning that it created substantial loss on money invested by shareholders. Ocuphire Pharma's management efficiency ratios could be used to measure how well Ocuphire Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/25/2024, Return On Tangible Assets is likely to drop to -0.19. In addition to that, Return On Capital Employed is likely to drop to -0.22. As of 04/25/2024, Liabilities And Stockholders Equity is likely to grow to about 56.6 M, while Total Current Liabilities is likely to drop slightly above 2.9 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.31 | 2.43 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | 2.31 | 2.43 | |
Enterprise Value Over EBITDA | (1.37) | (1.30) | |
Price Book Value Ratio | 1.30 | 1.24 | |
Enterprise Value Multiple | (1.37) | (1.30) | |
Price Fair Value | 1.30 | 1.24 | |
Enterprise Value | 14.5 M | 13.8 M |
The analysis of Ocuphire Pharma's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Ocuphire Pharma's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Ocuphire Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.242 |
Technical Drivers
As of the 25th of April, Ocuphire Pharma holds the Coefficient Of Variation of (515.03), risk adjusted performance of (0.11), and Variance of 16.19. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Ocuphire Pharma, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We are able to break down and analyze data for thirteen technical drivers for Ocuphire Pharma, which can be compared to its competitors. Please check Ocuphire Pharma market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Ocuphire Pharma is priced some-what accurately, providing market reflects its current price of 1.53 per share. Please also confirm Ocuphire Pharma jensen alpha, which is currently at (0.91) to check out the company can sustain itself at a future point.Ocuphire Pharma Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Ocuphire Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Ocuphire Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Ocuphire Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ocuphire Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ocuphire Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ocuphire Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ocuphire Pharma Predictive Daily Indicators
Ocuphire Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ocuphire Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ocuphire Pharma Forecast Models
Ocuphire Pharma's time-series forecasting models are one of many Ocuphire Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Ocuphire Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Ocuphire Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Ocuphire Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Ocuphire shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Ocuphire Pharma. By using and applying Ocuphire Stock analysis, traders can create a robust methodology for identifying Ocuphire entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.52) | (0.55) | |
Operating Profit Margin | (0.55) | (0.58) | |
Net Loss | (0.52) | (0.55) | |
Gross Profit Margin | 1.00 | 0.80 |
Current Ocuphire Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Ocuphire analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Ocuphire analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
20.2 | Strong Buy | 4 | Odds |
Most Ocuphire analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Ocuphire stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Ocuphire Pharma, talking to its executives and customers, or listening to Ocuphire conference calls.
Ocuphire Stock Analysis Indicators
Ocuphire Pharma stock analysis indicators help investors evaluate how Ocuphire Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Ocuphire Pharma shares will generate the highest return on investment. By understating and applying Ocuphire Pharma stock analysis, traders can identify Ocuphire Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow | 42.6 M | |
Common Stock Shares Outstanding | 21.6 M | |
Total Stockholder Equity | 49.9 M | |
Tax Provision | 12 K | |
Cash And Short Term Investments | 50.5 M | |
Cash | 50.5 M | |
Accounts Payable | 2.2 M | |
Net Debt | -50.5 M | |
50 Day M A | 2.1326 | |
Total Current Liabilities | 4 M | |
Other Operating Expenses | 29.6 M | |
Forward Price Earnings | 12.0048 | |
Stock Based Compensation | 3.5 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocuphire Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. To learn how to invest in Ocuphire Stock, please use our How to Invest in Ocuphire Pharma guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Ocuphire Stock analysis
When running Ocuphire Pharma's price analysis, check to measure Ocuphire Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ocuphire Pharma is operating at the current time. Most of Ocuphire Pharma's value examination focuses on studying past and present price action to predict the probability of Ocuphire Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ocuphire Pharma's price. Additionally, you may evaluate how the addition of Ocuphire Pharma to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Ocuphire Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocuphire Pharma. If investors know Ocuphire will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocuphire Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.882 | Quarterly Revenue Growth (0.96) | Return On Assets (0.13) | Return On Equity (0.21) |
The market value of Ocuphire Pharma is measured differently than its book value, which is the value of Ocuphire that is recorded on the company's balance sheet. Investors also form their own opinion of Ocuphire Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ocuphire Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocuphire Pharma's market value can be influenced by many factors that don't directly affect Ocuphire Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocuphire Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocuphire Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocuphire Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.